Showing 7221-7230 of 9461 results for "".
- Tattoo Removal Trends Revealed in Global Analysis of Over 200,000 Individualshttps://practicaldermatology.com/news/tattoo-removal-trends-revealed-in-global-analysis-of-over-200000-individuals/2474320/Laser tattoo removal is increasingly sought by individuals across the globe, according to new research presented at the American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando. The data were presente
- Survey Reveals Clinician Views on CHE's Impact on Quality of Lifehttps://practicaldermatology.com/news/Survey-Reveals-Clinician-Views-CHEs-Impact-Quality-Life/2474228/Ninety-five percent of US dermatology clinicians surveyed agreed moderate-to-severe chronic hand eczema (CHE) has a strong impact on patients’ work and home life, according to the second phase of a survey sponsored by LEO Pharma Inc., the company announced in a press release. The survey, w
- Machine Learning Model Flags HS Up to Two Years Before Diagnosis: Reporthttps://practicaldermatology.com/news/machine-learning-model-flags-hidradenitis-suppurativa-up-to-two-years-before-diagnosis/2474208/A machine learning model analyzing U.S. insurance claims data was able to predict hidradenitis suppurativa (HS) up to two years before formal diagnosis, a new study shows. "Because the individual symptoms of cysts and abscesse
- Increased Cost Diminishes Sunscreen Use: Reporthttps://practicaldermatology.com/news/cost-influences-sunscreen-use-raising-skin-cancer-risk-study-shows/2474206/Patients use less sunscreen when it’s more expensive, according to a brief report in the Journal of the American Academy of Dermatology. Researchers from the University of California, Sa
- FDA Approves Dupilumab for CSU in Adults 12 and Olderhttps://practicaldermatology.com/news/FDA-Approves-Dupilumab-CSU-Adults-12-Older/2474212/The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc. and Sanofi) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with histamine-1 (H1) ant
- Kenvue’s Ricciardone Explains New Data on the Value of Teamwork in Moisturizers and Retinoidshttps://practicaldermatology.com/news/Kenvues-Ricciardone-Explains-New-Data-Value-Teamwork-Moisturizers-Retinoids/2474166/Data presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, supported the “full sandwich” moisturizer method for new retinoid users who may experience sensitivity from retinization during the skin acclimation period while also suggesting that Neutrogena® H
- Melanoma Risk Model Validated in Global Studyhttps://practicaldermatology.com/news/international-study-strengthens-confidence-in-sentinel-node-prediction-tool/2474126/The Melanoma Institute Australia (MIA) sentinel node (SN) metastasis risk calculator has been validated in a large, multinational cohort, reinforcing its applicability across diverse populations and clinical settings. The MIA
- Bimekizumab Trials 'Raise the Bar' for HS, Dr. Vivian Shi Sayshttps://practicaldermatology.com/news/Bimekizumab-Trials-Raise-Bar-HS-Dr-Vivian-Shi-Says/2473933/More than half of hidradenitis suppurativa (HS) patients treated with bimekizumab (BIMZELX, UCB) had no draining tunnels (DTs) at 2 years, and 63.6% reported no or mild skin pain, compared to 10.0% at baseline, according to new data presented at the 2025 American Academy of Dermatology (AAD) Annu
- Continuous Abrocitinib Use Linked to Better Long-Term AD Outcomes: Studyhttps://practicaldermatology.com/news/continuous-abrocitinib-use-linked-to-better-long-term-ad-outcomes-study/2473925/A new real-world study suggests that sustained abrocitinib treatment and adherence to the full 12-week induction phase improved outcomes and delay relapse in patients with moderate to severe atopic dermatitis (AD). "Although c
- Rituximab Efficacious for Epidermolysis Bullosa Acquisita: Analysishttps://practicaldermatology.com/news/rituximab-shows-promise-for-epidermolysis-bullosa-acquisita/2473835/Data from a new systematic review indicate rituximab (RTX) may potentially be an effective treatment option for epidermolysis bullosa acquisita (EBA). Due to its chronic nature, management of EBA remains challenging, with remission and flare-up